The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis.
The effects of magnesium glycerophosphate oral therapy on spasticity was studied in a 35-year-old woman with severe spastic paraplegia resulting from multiple sclerosis (MS). We found a significant improvement in the spasticity after only 1 week from the onset of the treatment on the modified Ashworth scale, an improvement in the range of motion and in the measures of angles at resting position in lower limbs. No side-effects were reported and there was no weakness in the arms during the treatment.
Rossier
P
P
Rivermead Rehabilitation Centre, Abingdon Road, Oxford OX1 4XD, UK.
van Erven
S
S
Wade
D T
DT
D000284:Administration, Oral; D000328:Adult; D005260:Female; D005994:Glycerophosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D010264:Paraplegia / Q000209:etiology; D016059:Range of Motion, Articular; D013035:Spasm / Q000188:drug therapy / Q000209:etiology*
D005994:Glycerophosphates; D008274:Magnesium